Tecan Group (TECN) Q3 2025 TU earnings summary

Executive summary

• Achieved mid-single-digit local currency sales growth in Q3 2025, marking sequential improvement after declines in Q1 and Q2.

• Life Sciences Business saw a low-single-digit sales decline, while Partnering Business grew sales in the low teens percentage range.

• Order intake exceeded sales in both segments, with a book-to-bill ratio above 1.

Financial highlights

• Q3 2025 sales increased by a mid-single-digit percentage in local currencies compared to prior quarters.

• Adjusted EBITDA margin for full-year 2025 forecasted at 17.5% to 18.5% of sales, excluding restructuring and acquisition costs.

• Estimated net impact of US tariffs and exchange rates could reduce adjusted EBITDA margin by up to 200 basis points.

Outlook and guidance

• Full-year 2025 sales outlook confirmed: expected to be within a low single-digit percentage decline to low single-digit percentage growth in local currencies, likely in the lower half of the range.

• Mid-term outlook maintained, targeting mid- to high-single-digit organic growth under normal market conditions, with gradual end-market recovery.

• 2026 guidance to be provided with full-year 2025 results in March 2026.